Sex-related gap found for use of DMTs in MS patients ages 18-40

Despite evidence supporting the safety of disease-modifying therapies (DMTs) during pregnancy, women with multiple sclerosis (MS) in their childbearing years are significantly less likely than men in the same age range to receive these typically most... [6136 chars]